DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Telli M, Turner N, Mailliez A. et al.
Abstract P1-14-03: ABRAZO: Exposure-efficacy and -safety analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in a phase 2 open-label trial.
Cancer Res 2018;
78: P1-14-03-P11-14-03
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.